期刊
BREAST CANCER-BASIC AND CLINICAL RESEARCH
卷 13, 期 -, 页码 -出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1178223419829072
关键词
Breast cancer dormancy; drug resistance; clinical model; neoadjuvant therapy
类别
资金
- European Commission H2020 Marie Sklodowska Curie Action Individual Fellowship (H2020-MSCAIF) [658170]
- Breast Cancer Now
- Wellcome Trust Institutional Fund (ISSF3)
- Marie Curie Actions (MSCA) [658170] Funding Source: Marie Curie Actions (MSCA)
Neoadjuvant therapy, where patients receive systemic therapy before surgical removal of the tumour, can downstage tumours allowing breast-conserving surgery, rather than mastectomy. In addition to its impact on surgery, the neoadjuvant setting offers a valuable opportunity to monitor individual tumour response. The effectiveness of standard and/or potential new therapies can be tested in the neoadjuvant pre-surgical setting. It can potentially help to identify markers differentiating patients that will potentially benefit from continuing with the same or a different adjuvant treatment enabling personalised treatment. Characterising the molecular response to treatment over time can more accurately identify the significant differences between baseline samples that would not be identified without post-treatment samples. In this review, we discuss the potential and challenges of using the neoadjuvant setting in translational breast cancer research, considering the implications for improving our understanding of response to treatment, predicting therapy benefit, modelling breast cancer dormancy, and the development of drug resistance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据